www.lowdosenaltrexone.org www.ldninfo.org

Bernard Bihari, MD

Updated: May 18, 2010


Bernard Bihari, MD, was the discoverer of the clinical effects of LDN in humans. In his groundbreaking clinical trial of patients with HIV/AIDS at Downstate Medical Center in 1985-86, Bihari discovered the significant effectiveness of low dose naltrexone in protecting the battered immune systems of those who were infected. With that knowledge, he entered private practice in an attempt to counter the then untreatable disease.


Curriculum Vitae

BERNARD BIHARI, M.D.
November 11, 1931—May 16, 2010

EDUCATION
  • B.A. - Cornell University, Ithaca, N.Y. 1949-1953
  • M.D. - Harvard Medical School, Boston, Mass. 1953-1957
TRAINING
1962-1965 Resident, Department of Psychiatry, Columbia Presbyterian Medical Center, N.Y.S. Psychiatric Institute
1960-1962 Research Associate in Neurophysiology, Section on Physiology, Laboratory of Clinical Science, N.I.M.H., Bethesda, Maryland
1959-1960 Resident, Department of Neurology, Massachusetts General Hospital, Boston, Mass.
1958-1959 Resident, Department of Medicine, Beth Israel Hospital, Boston, Mass.
1957-1958 Intern, Department of Medicine, Beth Israel Hospital, Boston, Mass.
CERTIFICATION
  • Board Certified, American Board of Psychiatry and Neurology. April 14, 1970
  • New York State Medical License 088158
FACULTY APPOINTMENTS
2002-Present Attending Physician, Beth Israel Medical Center, New York, NY
1981-Present Clinical Associate Professor, SUNY / Health Science Center at Brooklyn
1968-1980 Assistant Professor, Department of Psychiatry, Mount Sinai School of Medicine
1959-1960 Instructor in Neurology, Harvard Medical School
EXPERIENCE
1991-Present Medical Director, Foundation for Integrative Research, Inc.,
New York, NY
1989-1991 Executive Director/Medical Director, Community Research Institute, New York, NY
1981-1989 Director, Division of Alcoholism and Drug Dependence, SUNY/Health Science Center at Brooklyn
1978-1980 Deputy Commissioner, Program Development and Evaluation (Deputy for Public Health Programs), NYC Department of Health
1977-1978 Commissioner, New York City Addiction Services Agency, and Deputy Commissioner for Addictions, NYC Department of Health
1974-1977 Assistant Commissioner for Addictions, NYC Department of Health
1972-1974 Chief, Alcoholism Treatment Program, Department of Psychiatry, Morris J. Bernstein Institute of Beth Israel Medical Center, New York
1971-1972 Chief, Drug Addiction Service, Department of Psychiatry, Morris J. Bernstein Institute of Beth Israel Medical Center, New York
RESEARCH PROJECTS
  1. Low Dose Naltrexone in the Treatment of AIDS.
    Principal Investigator: Bernard Bihari, MD
    Funded by Foundation for Integrative Research, at SUNY/Health Science Center at Brooklyn
    1985-1986
  2. HIV Maternal Fetal Transmission Study.
    Co-investigator: Bernard Bihari, MD
    Funded by National Cancer Institute and National Institute of Child Health and Human Development at SUNY/Health Science Center at Brooklyn
    1987-1990
  3. Collaborative Prospective Cohort Studies of Heterosexual Transmission of HIV and Related Retroviral Infections.
    Co-investigator: Bernard Bihari, MD
    Funded by National Institute of Health and National Institute of Allergies and Infectious Diseases at SUNY/Health Science Center at Brooklyn
    1987-1990
  4. Lentinan as an Immunomodulator (Phase 1/11 Placebo Controlled Dose Response Study of Lentinan in Patients with HIV Infection and 2000/500/mm CD4 Lymphocytes).
    Principal investigator: Bernard Bihari, MD, at CRI.
    Sponsored by Lenti-Chemico, Teaneck, NJ
    1989-1990
  5. Rifabutin Therapy for the Prevention of Mycobacterium-Avium Complex (MAC) Bacteremia in AIDS Patients with CD4 Counts = 200: A Double-Blind, Placebo-Controlled Trial.
    Principal Investigator: Bernard Bihari, MD at CRI.
    Sponsored by Adria Pharmaceutical, Columbus, Ohio
    1990-1993
  6. Methionine Enkephalin (MEK): Phase 1/11, Double-Blind, Placebo-Controlled; Its Safety, Toxicity and Possible Immune Modulatory Effects.
    Principal Investigator: Bernard Bihari, MD, at CRI
    Sponsored by TNI, Willmette, IL
    1990-1991
SELECTED BIBLIOGRAPHY

Evarts EV, Bental E, Bihari B, Huttenlocher P. Spontaneous discharge of single neurons during sleep and waking. Science 1962; No. 3505, 135:726.

Bental E, Bihari B. Evoked activity of single neurons in sensory association cortex of the cat. J. Neurophys. 1963; 26:207.

Bihari B, Richman A, Moran D. Heroin addicts among servicemen. Presented at the 1972 Annual Meeting American Psychiatric Association. Scientific Proceedings in Summary Form 125th Annual Meeting, American Psychiatric Association 1972. Summary Paper No. 221:246-247.

Bihari B. Alcoholism in M.M.T.P. patients: Etiological factors and treatment approaches. From the Proceedings, Fifth National Conference on Methadone Treatment, Washington D.C. 1973; 1:288-295.

Bihari B. Alcoholism and methadone maintenance. Amer. J. Drug and Alcohol Abuse 1974; No. 1, 1:79-87.

Bihari B. Drug dependency: Some etiological considerations. Amer. J. Drug and Alcohol Abuse 1976; No. 3, 3:409-123.

Begleiter H, Porjesz B, Bihari B, Kissin B. Event-related brain potentials in boys at risk for alcoholism. Science 1984; 225:1493-1496.

Bihari B, Ottomanelli G, Drury F, Ragone V. Fluctuation of T-cell subsets in repeated measures in AIDS patients. Letter to the Editor, AIDS Res. 1986; No. 4, 2:263-265.

Bihari B, Drury F, Ragone V, Ottomanelli G, Buimovici-Klein E, Orbe M, Foeste W, Thomas J, Kirk R. Low-dose naltrexone in the treatment of AIDS. Submitted for publication.

Nightingale S, Cameron W, Gordin F, Sullam. PM, Cohn DL, Chaisson R, Eron LJ, Sparti PD, Bihari B, Kaufman DL, Stern JJ, Pearce DD, Weinberg WG, LaMarca A, Siegal FP. Two controlled trials of rifabutin prophylaxis against mycobacterium avium complex infection in AIDS. N. Eng. J. Med. 1993; No. 12, 329:828-833.

SELECTED PAPERS PRESENTED AT CONFERENCES

Bihari B, Drury F, Ragone VP, Orbe MG, Foeste WF, Thomas JR, Kirk RP, Buimovici-KIein E, Kokayi K. Low-dose naltrexone in the treatment of the immune deficiency in AIDS and ARC. Presented at the 11 International Conferenceon AIDS, Paris, France June 1986.

Bihari B, Drury F, Ragone VP, Ottomanelli GA, Buimovici-Klein, E, Orbe MG Foeste WF, Thomas JR, Kirk RP. Low-dose naltrexone in the treatment of AIDS. Presented. at the III International Conference on AIDS, Washington D.C., June 1987.

Bihari B, Drury F, Ragone VP, Ottomanelli GA, Buimovici-Klein E. Alpha interferon as a marker and a secondary pathogenic factor in AIDS Presented at the III International Conference on AIDS, Washington D.C.,. June 1987.

Bihari B, Martin J, Seaman D. The use of disulfiram as an immunomodulating agent. IV International Conference on AIDS, Stockholm, Sweden, June 1988.

Bihari B, Drury F, Ragone VP, Ottomanelli GA, McCoy J, Buimovici-Klein E. Low-dose naltrexone in the treatment of AIDS. Presented at the IV International Conference on AIDS, Stockholm, Sweden, June 1988.

Hittelman J, Willoughby A, Mendez H, Silcott J, Shah P, Holman S, Glass L, Bihari B, Goedert J, Landesman S. Prospective neurodevelopmental outcome of infants with perinatally acquired HIV infection and their controls. The American Pediatric Society Conference on AIDS, Washington, D.C., May 1989.

Bihari B, Drury F, Ragone VP, Ottomanelli GA, Cannon G, Buimovici-Klein E. Low dose naltrexone in the treatment of AIDS: Long term follow-up results. Presented at the V International Conference on AIDS, Montreal, Canada, June 6, 1989.

Bihari B, Ottomanelli G. Defense mechanisms and HIV related behaviors in substance abusers. Presented at the V International Conference on AIDS, Montreal, Canada, June 6, 1989.

Bihari B. Impact on AIDS clinical trials of the use of non-approved therapies. Presented at the V International Conference on AIDS, Montreal, Canada, June 6, 1989.

Bihari B, Plotnikoff N, Freeman K. et al. Methionine Enkephalin in the treatment of ARC, VII International Conference on AIDS, Florence, June 1991 (Poster WB2137).